A review of mergers-and-acquisitions data in our Elsevier Strategic Transactions database suggests that strategic buyers are more interested than ever in hedging their bets by structuring acquisitions around earn-out payments, which come due once the acquired company delivers on its promises.
Medical Device Earn-Outs More Common As Buyers Hedge Bets
No one particularly enjoys taking risks these days. A fair number of venture capitalists, for example, are increasingly basing their investment decisions upon how a company has mitigated and managed every conceivable risk facing start-ups today – technology, regulatory approval, and reimbursement. In exchange for safety, venture capitalists might be willing to invest a little more capital and accept slightly less frothy rates of returns on investment. Safety, like everything, comes with a price.
Corporate acquirers, not surprisingly, are equally if not more risk adverse. Clearly, large medical device corporations still find a rich source of innovation outside their own corporate walls. And they're willing to pay the price to secure what they see as the best opportunities for growth. But they're being cautious. A review of merger-and-acquisition data in Elsevier's Strategic Transactions suggests that strategic buyers are more interested than ever in hedging their bets by structuring acquisitions around earn-out payments, which come due once the acquired company delivers on its promises.
Clearly, sellers would prefer to avoid the structured earn-out, choosing to receive their full payment up front. And until 2008, when the wheels popped off the economy's wagon, sellers – venture capitalists or corporate owners looking for a spin-out – sat in the driver's seat at the negotiating table. In 2008, only 9% of the medical device acquisitions recorded in our database reported an earn-out clause, a considerable drop from the 20% in 2007. But the good times were short-lived. That percentage climbed to 13% in 2009 – although it's a bit of a surprise that it wasn't higher – and so far it's 31% year-to-date in 2010.
Strategic acquirers want to pay for performance. But the positive news for sellers is that while the number of deals with earn-out elements is rising, the percentage of the up-front payment also remains higher than in more recent years.The sample size is small, but buyers in 2010 are paying roughly 70% of the purchase price up front. Medtronic Inc., for example, agreed to pay $350 million for interventional cardio device developer Invatec SRL, with an additional $150 million set aside in earn-outs if certain milestones are reached. Unfortunately, although more than 40 companies were used in these figures, we didn't include deals where terms weren't available. Medtronic's acquisitions of CoreValve Inc.
Purchase this article online or get it FREE when you subscribe to Start Up.
Companies mentioned in this article:
Medtronic Ablation Frontiers LLC
Medtronic CoreValve LLC
Elsevier Business Intelligence announces the publication of a new Special Report "Bigger, Tougher,Faster"- Preparing for the New FDA. When the inspector comes calling ... will you be ready?
This 16-page report originally published in "The Silver Sheet". Learn more...
About Start Up
No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985 9512
.jpg)
.jpg)
Comments